Greenwich LifeSciences Says Audit of 2025 Form 10-K Filing in Final Stages of Approval

MT Newswires Live

06/01

Greenwich LifeSciences (GLSI) said Monday its new auditor continues to audit the company's Form 10-K for the year ended Dec. 31, 2025, which includes the 2024 audit.

The company said it believes the audit is in its final stages of approval.

Greenwich LifeSciences said accounts payable adjustments were related to its ongoing global phase III clinical trial and an unexpectedly large increase in screening and patient enrollment in Europe during 2024 and 2025.

The company does not believe the adjustments are material to it or its investors and that they do not change the company's fundamentals, it said.

Greenwich LifeSciences said that the shift in expenses does not affect its cash balance or net cash used in operating activities. The company said it had a cash balance of $10.5 million as of March 31, which it said exceeded its 2025 net cash used in operating activities of around $9.9 million.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hans/news/2640558259"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2640558259\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2640558259?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-01 18:48","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2640558259","market":"nz","top_or_hot":-1,"title":"Greenwich LifeSciences Says Audit of 2025 Form 10-K Filing in Final Stages of Approval","media":"MT Newswires Live","content":"<html><body><p> Greenwich LifeSciences (GLSI) said Monday its new auditor continues to audit the company's Form 10-<a href=\"https://laohu8.com/S/TKKD.SI\">K</a> for the year ended Dec. 31, 2025, which includes the 2024 audit.</p><p>The company said it believes the audit is in its final stages of approval.</p><p>Greenwich LifeSciences said accounts payable adjustments were related to its ongoing global phase III clinical trial and an unexpectedly large increase in screening and patient enrollment in Europe during 2024 and 2025.</p><p>The company does not believe the adjustments are material to it or its investors and that they do not change the company's fundamentals, it said.</p><p>Greenwich LifeSciences said that the shift in expenses does not affect its cash balance or net cash used in operating activities. The company said it had a cash balance of $10.5 million as of March 31, which it said exceeded its 2025 net cash used in operating activities of around $9.9 million.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Greenwich LifeSciences Says Audit of 2025 Form 10-K Filing in Final Stages of Approval</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGreenwich LifeSciences Says Audit of 2025 Form 10-K Filing in Final Stages of Approval\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-06-01 18:48</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Greenwich LifeSciences (GLSI) said Monday its new auditor continues to audit the company's Form 10-<a href=\"https://laohu8.com/S/TKKD.SI\">K</a> for the year ended Dec. 31, 2025, which includes the 2024 audit.</p><p>The company said it believes the audit is in its final stages of approval.</p><p>Greenwich LifeSciences said accounts payable adjustments were related to its ongoing global phase III clinical trial and an unexpectedly large increase in screening and patient enrollment in Europe during 2024 and 2025.</p><p>The company does not believe the adjustments are material to it or its investors and that they do not change the company's fundamentals, it said.</p><p>Greenwich LifeSciences said that the shift in expenses does not affect its cash balance or net cash used in operating activities. The company said it had a cash balance of $10.5 million as of March 31, which it said exceeded its 2025 net cash used in operating activities of around $9.9 million.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"GLSI","symbol_name":"Greenwich Lifesciences Inc","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2640558259","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2640558259","pubTimestamp":1780310925,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Greenwich LifeSciences  said Monday its new auditor continues to audit the company's Form 10-K for the year ended Dec. 31, 2025, which includes the 2024 audit.The company said it believes the audit is in its final stages of approval.Greenwich LifeSciences said accounts payable adjustments were related to its ongoing global phase III clinical trial and an unexpectedly large increase in screening and patient enrollment in Europe during 2024 and 2025.The company does not believe the adjustments are material to it or its investors and that they do not change the company's fundamentals, it said.Greenwich LifeSciences said that the shift in expenses does not affect its cash balance or net cash used in operating activities. The company said it had a cash balance of $10.5 million as of March 31, which it said exceeded its 2025 net cash used in operating activities of around $9.9 million.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"GLSI":"Greenwich Lifesciences Inc","BK4139":"生物科技"},"translate_title":"Greenwich LifeSciences表示对2025年10-K表格备案的审计已进入批准的最后阶段","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"GLSI":1},"content_text":"Greenwich LifeSciences (GLSI) said Monday its new auditor continues to audit the company's Form 10-K for the year ended Dec. 31, 2025, which includes the 2024 audit.The company said it believes the audit is in its final stages of approval.Greenwich LifeSciences said accounts payable adjustments were related to its ongoing global phase III clinical trial and an unexpectedly large increase in screening and patient enrollment in Europe during 2024 and 2025.The company does not believe the adjustments are material to it or its investors and that they do not change the company's fundamentals, it said.Greenwich LifeSciences said that the shift in expenses does not affect its cash balance or net cash used in operating activities. The company said it had a cash balance of $10.5 million as of March 31, which it said exceeded its 2025 net cash used in operating activities of around $9.9 million.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}